

Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021

<https://marketpublishers.com/r/S3B2BD6EE546EN.html>

Date: December 2021

Pages: 91

Price: US\$ 3,500.00 (Single User License)

ID: S3B2BD6EE546EN

Abstracts

Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021

SUMMARY

Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 3, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Infectious Disease, Respiratory and Undisclosed which include indications Medulloblastoma, Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/Nevoid Basal Cell Carcinoma Syndrome), Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Myelomonocytic Leukemia (CMML), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bone Disorders, Coccidioidomycosis, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrosis, Graft Versus Host Disease (GVHD), Idiopathic Pulmonary Fibrosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer,

Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Small-Cell Lung Cancer and Unspecified.

The latest report GMDHC3047TDB – Smoothened Homolog – Drugs In Development, 2021, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)

The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects

The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

- Introduction
- Global Markets Direct Report Coverage
- Smoothened Homolog (Protein Gx or SMO) - Overview
- Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
- Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
- Smoothened Homolog (Protein Gx or SMO) - Dormant Products
- Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
- Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dormant Products, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

I would like to order

Product name: Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/S3B2BD6EE546EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S3B2BD6EE546EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970